Q203

  Cat. No.:  DC10109   Featured
Chemical Structure
1334719-95-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Q203 is a promising new clinical candidate for the treatment of tuberculosis.
Cas No.: 1334719-95-7
Chemical Name: Q-203;Q 203;IAP 6;IAP-6;IAP6
Synonyms: Q-203;Q 203;IAP 6;IAP-6;IAP6
SMILES: CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)OC(F)(F)F
Formula: C29H28ClF3N4O2
M.Wt: 557.01
Sotrage: 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
Description: Q203 (IAP6) is a midazopyridine amide compound. Q203 is active against Mycobacterium tuberculosis H37Rv with an MIC50 of 2.7 nM in culture broth medium.
In Vivo: Q203 is efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight. Q203 displays pharmacokinetic and safety profiles compatible with once-daily dosing. Q203 has a bioavailability of 90% and a terminal half-life of 23.4 h. The volume of distribution is moderate (5.27 l per kg body weight), and the systemic clearance is low (4.03 mL/min per kg). After 4 weeks of treatment, reductions of 90%, 99% and 99.9% in M. tuberculosis H37Rv bacterial load is observed in the groups treated with Q203 at 0.4, 2 and 10 mg per kg body weight, respectively[1].
In Vitro: Imidazopyridine amide (IPA) compounds block Mycobacterium tuberculosis growth by targeting the respiratory cytochrome bc1 complex. The optimized IPA compound Q203 inhibits the growth of MDR and XDR Mycobacterium tuberculosis clinical isolates in culture broth medium in the low nanomolar range. Q203 is active against the reference strain Mycobacterium tuberculosis H37Rv with MIC50s of 2.7 nM in culture broth medium and 0.28 nM inside macrophages[1].
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC10109 Q203 Q203 is a promising new clinical candidate for the treatment of tuberculosis.
DC11277 Zoliflodacin(AZD0914) Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor.
DC10733 Sutezolid (PNU-100480) Sutezolid (PNU-100480) is an oxazolidinone antimicrobial being developed for the treatment of tuberculosis.
DC8032 Solithromycin Solithromycin is a novel ketolide antibiotic.
DC10441 Relebactam Relebactam is a diazabicyclooctane inhibitor with activity against a wide spectrum of β-lactamases, including class A (extended-spectrum β-lactamases [ESBLs] and KPC) and class C (AmpC) enzymes.
DC9723 PBTZ169 PBTZ169 is a decaprenyl-phosphoribose-epimerase (DprE1) inhibitor.
DC11273 Murepavadin (POL7080) Murepavadin is a novel class of highly specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas infections.
DC8928 Minocycline hydrochloride Minocycline is a tetracycline antibiotic with neuroprotective, antiapoptotic, anti-inflammatory and antimicrobial effects.
DC1057 Fidaxomicin (Dificid) Fidaxomicin, is an antibiotic that belongs to the class of macrocylic antibiotics.
DC10612 Delpazolid (LCB01-0371) Delpazolid (LCB01-0371) is a new oxazolidinone with cyclic amidrazone.
X